Table of Contents Author Guidelines Submit a Manuscript
Journal of Nutrition and Metabolism
Volume 2010, Article ID 467316, 11 pages
http://dx.doi.org/10.1155/2010/467316
Research Article

Hop and Acacia Phytochemicals Decreased Lipotoxicity in 3T3-L1 Adipocytes, db/db Mice, and Individuals with Metabolic Syndrome

1Department of Research & Development, MetaProteomics, LLC, 9770 44th Avenue NW, Suite 100, Gig Harbor, WA 98332, USA
2Bionexus, Cornell Technology Park, 30 Brown Road, Ithaca, NY 14850, USA

Received 20 January 2010; Accepted 23 February 2010

Academic Editor: Maria Luz Fernandez

Copyright © 2010 Deanna M. Minich et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. S. Ford, “Prevalence of the metabolic syndrome defined by the international diabetes federation among adults in the U.S.,” Diabetes Care, vol. 28, no. 11, pp. 2745–2749, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. C. M. Alexander, P. B. Landsman, S. M. Teutsch, and S. M. Haffner, “NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older,” Diabetes, vol. 52, no. 5, pp. 1210–1214, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Isomaa, P. Almgren, T. Tuomi et al., “Cardiovascular morbidity and mortality associated with the metabolic syndrome,” Diabetes Care, vol. 24, no. 4, pp. 683–689, 2001. View at Google Scholar
  4. R. C. Turner, C. A. Cull, V. Frighi, and R. R. Holman, “Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49),” Journal of the American Medical Association, vol. 281, no. 21, pp. 2005–2012, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. J. D. McGarry, “Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes,” Diabetes, vol. 51, no. 1, pp. 7–18, 2002. View at Google Scholar · View at Scopus
  6. S. Schinner, W. A. Scherbaum, S. R. Bornstein, and A. Barthel, “Molecular mechanisms of insulin resistance,” Diabetic Medicine, vol. 22, no. 6, pp. 674–682, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. M. D. Ivorra, M. Paya, and A. Villar, “A review of natural products and plants as potential antidiabetic drugs,” Journal of Ethnopharmacology, vol. 27, no. 3, pp. 243–275, 1989. View at Publisher · View at Google Scholar · View at Scopus
  8. W. Jia, W. Gaoz, and L. Tang, “Antidiabetic herbal drugs officially approved in China,” Phytotherapy Research, vol. 17, no. 10, pp. 1127–1134, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Jung, M. Park, H. C. Lee, Y.-H. Kan, E. S. Kang, and S. K. Kim, “Antidiabetic agents from medicinal plants,” Current Medicinal Chemistry, vol. 13, no. 10, pp. 1203–1218, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. H. X. Wang and T. B. Ng, “Natural products with hypoglycemic, hypotensive, hypocholesterolemic, antiatherosclerotic and antithrombotic activities,” Life Sciences, vol. 65, no. 25, pp. 2663–2677, 1999. View at Google Scholar · View at Scopus
  11. D. C. Anderson Jr., “Pharmacologic prevention or delay of type 2 diabetes mellitus,” The Annals of Pharmacotherapy, vol. 39, no. 1, pp. 102–109, 2005. View at Google Scholar
  12. S. K. Swanston-Flatt, C. Day, P. R. Flatt, B. J. Gould, and C. J. Bailey, “Glycaemic effects of traditional European plant treatments for diabetes. Studies in normal and streptozotocin diabetic mice,” Diabetes Research, vol. 10, no. 2, pp. 69–73, 1989. View at Google Scholar · View at Scopus
  13. M. L. Tripp, V. R. Konda, G. Darland et al., “Rho-iso-a acids and tetrahydro-iso-a acids are selective protein kinase inhibitors which potently reduce inflammation in macrophages in vitro and in the collagen-induced rheumatoid arthritis model in vivo,” Acta Hort (ISHS), vol. 848, pp. 221–234, 2009. View at Google Scholar
  14. H. G. Preuss, D. Bagchi, and M. Bagchi, “Protective effects of a novel niacin-bound chromium complex and a grape seed proanthocyanidin extract on advancing age and various aspects of syndrome X,” Annals of the New York Academy of Sciences, vol. 957, pp. 250–259, 2002. View at Google Scholar · View at Scopus
  15. H.-Y. Tsai, L.-Y. Wu, and L. S. Hwang, “Effect of a proanthocyanidin-rich extract from longan flower on markers of metabolic syndrome in fructose-fed rats,” Journal of Agricultural and Food Chemistry, vol. 56, no. 22, pp. 11018–11024, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. A. J. Hall, J. G. Babish, G. K. Darland et al., “Safety, efficacy and anti-inflammatory activity of rho iso-a-acids from hops,” Phytochemistry, vol. 69, no. 7, pp. 1534–1547, 2008. View at Google Scholar
  17. R. H. Lerman, D. M. Minich, G. Darland et al., “Enhancement of a modified mediterranean-style, low glycemic load diet with specific phytochemicals improves cardiometabolic risk factors in subjects with metabolic syndrome and hypercholesterolemia in a randomized trial,” Nutrition & Metabolism, vol. 5, p. 29, 2008. View at Google Scholar
  18. M.-E. Xu, S.-Z. Xiao, Y.-H. Sun, Y. Ou-Yang, C. Guan, and X.-X. Zheng, “A preadipocyte differentiation assay as a method for screening potential anti-type II diabetes drugs from herbal extracts,” Planta Medica, vol. 72, no. 1, pp. 14–19, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. R. Kasturi and V. C. Joshi, “Hormonal regulation of stearoyl coenzyme a desaturase activity and lipogenesis during adipose conversion of 3T3-L1 cells,” Journal of Biological Chemistry, vol. 257, no. 20, pp. 12224–12230, 1982. View at Google Scholar · View at Scopus
  20. M. C. Berenbaum, “What is synergy?” Pharmacological Reviews, vol. 41, no. 2, pp. 93–141, 1989. View at Google Scholar · View at Scopus
  21. F. I. Katch and W. D. McArdle, “Validity of body composition prediction equations for college men and women,” American Journal of Clinical Nutrition, vol. 28, no. 2, pp. 105–109, 1975. View at Google Scholar · View at Scopus
  22. I. Raz, R. Eldor, S. Cernea, and E. Shafrir, “Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage,” Diabetes/Metabolism Research and Reviews, vol. 21, no. 1, pp. 3–14, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. E. S. Ford, C. Li, G. Zhao, W. S. Pearson, and A. H. Mokdad, “Hypertrigly ceridemia and its pharmacologic treatment among US adults,” Archives of Internal Medicine, vol. 169, no. 6, pp. 572–578, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Scuteri, C. H. Morrell, S. S. Najjar et al., “Longitudinal paths to the metabolic syndrome: can the incidence of the metabolic syndrome be predicted? The Baltimore longitudinal study of aging,” Journals of Gerontology, vol. 64, no. 5, pp. 590–598, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. N. Sattar, A. McConnachie, A. G. Shaper et al., “Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies,” Lancet, vol. 371, no. 9628, pp. 1927–1935, 2008. View at Google Scholar
  26. A. F. H. Stalenhoef and J. de Graaf, “Association of fasting and nonfasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small dense LDL,” Current Opinion in Lipidology, vol. 19, no. 4, pp. 355–361, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. W. B. Kannel and R. S. Vasan, “Triglycerides as vascular risk factors: new epidemiologic insights,” Current Opinion in Cardiology, vol. 24, no. 4, pp. 345–350, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. J. E. Hokanson and M. A. Austin, “Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies,” Journal of Cardiovascular Risk, vol. 3, no. 2, pp. 213–219, 1996. View at Google Scholar · View at Scopus
  29. P. Blackburn, I. Lemieux, N. Almeras et al., “The hypertriglyceridemic waist phenotype versus the National Cholesterol Education Program-Adult Treatment Panel III and International Diabetes Federation clinical criteria to identify high-risk men with an altered cardiometabolic risk profile,” Metabolismml: Clinical and Experimental, vol. 58, no. 8, pp. 1123–1130, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. F. Fantin, V. Di Francesco, A. Rossi et al., “Abdominal obesity and subclinical vascular damage in the elderly,” Journal of Hypertension, vol. 28, no. 2, pp. 333–339, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. C. M. Kusminski, S. Shetty, L. Orci, R. H. Unger, and P. E. Scherer, “Diabetes and apoptosis: lipotoxicity,” Apoptosis, vol. 14, no. 12, pp. 1484–1495, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Bo, G. Ciccone, C. Baldi et al., “Effectiveness of a lifestyle intervention on metabolic syndrome. A randomized controlled trial,” Journal of General Internal Medicine, vol. 22, no. 12, pp. 1695–1703, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. D. De Keukeleirc, “Fundamentals of beer and hop chemistry,” Química Nova, vol. 23, no. 1, pp. 108–112, 2000. View at Google Scholar · View at Scopus
  34. M. Shimura, A. Hasumi, T. Minato et al., “Isohumulones modulate blood lipid status through the activation of PPARa,” Biochimica et Biophysica Acta, vol. 1736, no. 1, pp. 51–60, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Yajima, E. Ikeshima, M. Shiraki et al., “Isohumulones, bitter acids derived from hops, activate both peroxisome proliferator-activated receptor a and ? and reduce insulin resistance,” Journal of Biological Chemistry, vol. 279, no. 32, pp. 33456–33462, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Stancakova, M. Javorsky, T. Kuulasmaa, S. M. Haffner, J. Kuusisto, and M. Laakso, “Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 finnish men,” Diabetes, vol. 58, no. 5, pp. 1212–1221, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. Step i, step ii and tlc diets, American Heart Association, 2010.
  38. P. B. Geil, J. W. Anderson, and N. J. Gustafson, “Women and men with hypercholesterolemia respond similarly to an American Heart Association step 1 diet,” Journal of the American Dietetic Association, vol. 95, no. 4, pp. 436–441, 1995. View at Google Scholar · View at Scopus
  39. L. B. Bunyard, K. E. Dennis, and B. J. Nicklas, “Dietary intake and changes in lipoprotein lipids in obese, postmenopausal women placed on an American Heart Association Step 1 diet,” Journal of the American Dietetic Association, vol. 102, no. 1, pp. 52–57, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Y. Bae, J. M. Keenan, P. Fontaine, J. Wenz, C. M. Ripsin, and D. J. McCaffrey, “Plasma lipid response and nutritional adequacy in hypercholesterolemic subjects on the American Heart Association Step-One Diet,” Archives of Family Medicine, vol. 2, no. 7, pp. 765–772, 1993. View at Google Scholar · View at Scopus
  41. A. H. Lichtenstein, L. J. Appel, M. Brands et al., “Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee,” Circulation, vol. 114, no. 1, pp. 82–96, 2006. View at Publisher · View at Google Scholar · View at Scopus